In addition to the smaller particle size and bioinspired properties of bLP versus counterpart liposomal formulations, the D-bLP-mediated TECA strategy would certainly account for the notable therapeutic outcomes on tumor relapse and metastasis (Fig. 9). This evidence concerns the gene DYNLRB1 and neoplasm.